Pipeline gap looms for Immunex

Immunex Corp.'s two recent clinical setbacks could leave it with a weak middle in its product pipeline. The company discontinued a Phase II/III trial of its Enbrel etanercept in patients with chronic heart failure

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE